Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05603910 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
A Phase 1 study of Recurrent Endometrial Carcinoma and Unresectable Endometrial Carcinoma, sponsored by Aaron Wolfson.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05603910 is a Phase 1 study of Recurrent Endometrial Carcinoma and Unresectable Endometrial Carcinoma that is actively recruiting participants, run by Aaron Wolfson. The registered enrollment target is 18 participants, below the 252-participant average among 19 other Recurrent Endometrial Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05603910, a Phase 1 study of Recurrent Endometrial Carcinoma and Unresectable Endometrial Carcinoma, is actively recruiting participants, sponsored by Aaron Wolfson.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation therapy, to support cancer cells in multiplying and spreading to other body sites.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- RADIATION Hypofractionated External Beam Radiation Therapy
- DRUG Lenvatinib
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-04-15 |
| Est. Completion | 2030-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05603910
The ClinicalTrials.gov registry entry for NCT05603910 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 19 other Recurrent Endometrial Carcinoma trials with a reported enrollment target (93% lower). The listed sponsor is Aaron Wolfson, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Endometrial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05603910 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05603910 about?
NCT05603910 is a clinical study titled "Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma". The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation therapy, to support cancer cells in multiplying and spreading to other b...
What is the current status of trial NCT05603910?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-04-15. Estimated completion is 2030-04-15.
What conditions does trial NCT05603910 study?
This clinical trial studies the following conditions: Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma.
What interventions are being tested in trial NCT05603910?
The interventions under investigation include: Pembrolizumab (DRUG), Hypofractionated External Beam Radiation Therapy (RADIATION), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT05603910?
This trial is sponsored by Aaron Wolfson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05603910 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RECRUITING · Phase 1
-
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
RECRUITING · Phase 1
-
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Endometrial Carcinoma
All registered trials for this condition
Unresectable Endometrial Carcinoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.